Christopher Nixon Cox - 12 May 2026 Form 4 Insider Report for Alto Neuroscience, Inc. (ANRO)

Reporting relationship: Director
Issuer ticker: ANRO
Reported as of: 12 May 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 14 May 2026, 16:58:43 UTC
Prior SEC filing: 16 Mar 2026
Next SEC filing: 21 May 2026
Source filing: View source filing
Reporting owner signature: /s/ Erin R. McQuade, Attorney-in-Fact

Key filing fact

Christopher Nixon Cox filed Form 4 for Alto Neuroscience, Inc. (ANRO) on 14 May 2026.

Key facts

This page summarizes Christopher Nixon Cox's Form 4 filing for Alto Neuroscience, Inc. (ANRO).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 14 May 2026, 16:58.

Change

Previous filing in this sequence was filed on 16 Mar 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002008212 Primary reporting owner

Cox Christopher Nixon

Relationship: Director
Address: C/O ALTO NEUROSCIENCE, INC., 650 CASTRO STREET, SUITE 450, MOUNTAIN VIEW
Signature: /s/ Erin R. McQuade, Attorney-in-Fact
Signature date: 14 May 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ANRO transaction Derivative

Stock Option (right to buy)

Award

Transaction value
Shares: +10,958
Change %
Price: $0.000000^*
Shares after: 10,958
Date: 12 May 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 10,958
Exercise price: $24.63
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The shares underlying the option shall vest on the earlier of the one-year anniversary of the date of grant and the date of Issuer's next Annual Meeting following the date of grant, subject to the Reporting Person's continuous service through such vesting date.

Footnote F2

This option was issued to the Reporting Person pursuant to the Issuer's Non-Employee Director Compensation Policy, and was not sold to the Reporting Person. As such, the Reporting person did not pay any consideration for the derivative securities.